cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform

Reuters

Jan 30

cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform

cbdMD has acquired substantially all assets of Bluebird Botanicals, a pioneer in hemp-derived wellness products known for its scientific discipline and proactive regulatory engagement. The acquisition brings Bluebird’s established self-affirmed GRAS (Generally Recognized As Safe) determination for a full-spectrum hemp extract containing naturally occurring THC into cbdMD’s portfolio. cbdMD plans to integrate Bluebird’s scientific and regulatory assets with its own clinical and toxicology foundation, creating a comprehensive safety and regulatory dossier for both broad-spectrum and full-spectrum cannabinoid formulations. The company is also preparing a new self-affirmed GRAS determination for its broad-spectrum products and aims to further strengthen Bluebird’s existing GRAS dossier under a unified regulatory strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607903777"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607903777\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607903777?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 01:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607903777","market":"nz","top_or_hot":-1,"title":"cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        cbdMD has acquired substantially all assets of Bluebird Botanicals, a pioneer in hemp-derived wellness products known for its scientific discipline and proactive regulatory engagement. The acquisition brings Bluebird’s established self-affirmed GRAS (Generally Recognized As Safe) determination for a full-spectrum hemp extract containing naturally occurring THC into cbdMD’s portfolio. cbdMD plans to integrate Bluebird’s scientific and regulatory assets with its own clinical and toxicology foundation, creating a comprehensive safety and regulatory dossier for both broad-spectrum and full-spectrum cannabinoid formulations. The company is also preparing a new self-affirmed GRAS determination for its broad-spectrum products and aims to further strengthen Bluebird’s existing GRAS dossier under a unified regulatory strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\ncbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 01:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        cbdMD has acquired substantially all assets of Bluebird Botanicals, a pioneer in hemp-derived wellness products known for its scientific discipline and proactive regulatory engagement. The acquisition brings Bluebird’s established self-affirmed GRAS (Generally Recognized As Safe) determination for a full-spectrum hemp extract containing naturally occurring THC into cbdMD’s portfolio. cbdMD plans to integrate Bluebird’s scientific and regulatory assets with its own clinical and toxicology foundation, creating a comprehensive safety and regulatory dossier for both broad-spectrum and full-spectrum cannabinoid formulations. The company is also preparing a new self-affirmed GRAS determination for its broad-spectrum products and aims to further strengthen Bluebird’s existing GRAS dossier under a unified regulatory strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YCBD","symbol_name":"cbdMD, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL7w47xD:1","article_id":"2607903777","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607903777","pubTimestamp":1769709439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"cbdMD has acquired substantially all assets of Bluebird Botanicals, a pioneer in hemp-derived wellness products known for its scientific discipline and proactive regulatory engagement. The acquisition brings Bluebird’s established self-affirmed GRAS  determination for a full-spectrum hemp extract containing naturally occurring THC into cbdMD’s portfolio. cbdMD plans to integrate Bluebird’s scientific and regulatory assets with its own clinical and toxicology foundation, creating a comprehensive safety and regulatory dossier for both broad-spectrum and full-spectrum cannabinoid formulations. The company is also preparing a new self-affirmed GRAS determination for its broad-spectrum products and aims to further strengthen Bluebird’s existing GRAS dossier under a unified regulatory strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"YCBD":"cbdMD, Inc.","BK4007":"制药"},"translate_title":"cbdMD收购Bluebird Botanicals扩大大麻素监管平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YCBD":0.9},"content_text":"cbdMD Acquires Bluebird Botanicals to Expand Cannabinoid Regulatory Platform\n    \n\n        cbdMD has acquired substantially all assets of Bluebird Botanicals, a pioneer in hemp-derived wellness products known for its scientific discipline and proactive regulatory engagement. The acquisition brings Bluebird’s established self-affirmed GRAS (Generally Recognized As Safe) determination for a full-spectrum hemp extract containing naturally occurring THC into cbdMD’s portfolio. cbdMD plans to integrate Bluebird’s scientific and regulatory assets with its own clinical and toxicology foundation, creating a comprehensive safety and regulatory dossier for both broad-spectrum and full-spectrum cannabinoid formulations. The company is also preparing a new self-affirmed GRAS determination for its broad-spectrum products and aims to further strengthen Bluebird’s existing GRAS dossier under a unified regulatory strategy.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}